{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:33Z","timestamp":1790931333019,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["14129"],"award-info":[{"award-number":["14129"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Anaplastic thyroid carcinoma (ATC) is a rare and aggressive malignancy with a median overall survival (OS) of approximately 2 months. The prognostic value of\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose positron emission tomography\/computed tomography ([\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT) in ATC remains unclear. This study aims to evaluate the prognostic significance of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT parameters in ATC patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study analyzed 34 patients diagnosed with ATC between January 2010 and October 2024 who underwent initial staging with [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT. Data collected included standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), along with patient and tumor characteristics. The relationships between these parameters and survival were assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      OS was 48 days (IQR: 27\u2013134). In univariate analysis, MTV (HR\u2009=\u20091.44,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009) was significantly associated with poorer OS. Surgery was associated with a significantly decreased hazard of mortality (HR, 0.418; 95% CI, 0.188\u20130.929;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.032), as was radiotherapy (HR, 0.423; 95% CI, 0.220\u20130.977;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.026).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study identifies MTV as a significant prognostic markers in univariate analysis for patients with ATC, highlighting the utility of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT in predicting patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08100-0","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:23:40Z","timestamp":1785399820000},"page":"7327-7335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of volume-based metabolic parameters of [18F]FDG PET\/CT in anaplastic thyroid carcinoma"],"prefix":"10.1007","volume":"53","author":[{"given":"H. I.","family":"Coerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. P.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van Houten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. P.","family":"Links","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. H.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. C.D.","family":"van der Rijt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. M.","family":"van Ginhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. T.","family":"Netea-Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.C.","family":"van Treijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Medici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"de Keizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kruijff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7161-0979","authenticated-orcid":false,"given":"F. A.","family":"Verburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"8100_CR1","unstructured":"Nederlandse Kankerregistratie I. Schildklierkanker. 2025."},{"issue":"2","key":"8100_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/EJE-20-0080","volume":"183","author":"M de Ridder","year":"2020","unstructured":"de Ridder M, van Nieveen E, Engelsman A, Kapiteijn E, Kl\u00fcmpen H-J, Rasch CRN. Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades. Eur J Endocrinol. 2020;183(2):203\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"8100_CR3","first-page":"5888","volume":"11","author":"B Lin","year":"2019","unstructured":"Lin B, Ma H, Ma M, Zhang Z, Sun Z, Hsieh Iy, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J translational Res. 2019;11(9):5888.","journal-title":"Am J translational Res"},{"issue":"3","key":"8100_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer guidelines task force. Thyroid. 2021;31(3):337\u201386.","journal-title":"Thyroid"},{"issue":"10","key":"8100_CR5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/thy.2020.0086","volume":"30","author":"B Xu","year":"2020","unstructured":"Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid. 2020;30(10):1505\u201317.","journal-title":"Thyroid"},{"issue":"10","key":"8100_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-020-00776-2","volume":"21","author":"W Alobuia","year":"2020","unstructured":"Alobuia W, Gillis A, Kebebew E. Contemporary management of anaplastic thyroid cancer. Curr Treat Options Oncol. 2020;21(10):1\u201315.","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"8100_CR7","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1089\/thy.2012.0302","volume":"22","author":"RC Smallridge","year":"2012","unstructured":"Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104\u201339.","journal-title":"Thyroid"},{"issue":"6","key":"8100_CR8","first-page":"930","volume":"45","author":"N Avril","year":"2004","unstructured":"Avril N. GLUT1 expression in tissue and 18F-FDG uptake. J Nucl Med. 2004;45(6):930\u20132.","journal-title":"J Nucl Med"},{"issue":"7","key":"8100_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1089\/thy.2007.0350","volume":"18","author":"TV Bogsrud","year":"2008","unstructured":"Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid. 2008;18(7):713\u20139.","journal-title":"Thyroid"},{"issue":"9","key":"8100_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1089\/105072502760339307","volume":"12","author":"J Schonberger","year":"2002","unstructured":"Schonberger J, Ruschoff J, Grimm D, Marienhagen J, Rummele P, Meyringer R, et al. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid. 2002;12(9):747\u201354.","journal-title":"Thyroid"},{"issue":"16","key":"8100_CR11","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.3390\/cancers13164228","volume":"13","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Chang H-S, Ryu YH. Prognostic role of pre-treatment [18F] FDG PET\/CT in patients with anaplastic thyroid cancer. Cancers. 2021;13(16):4228.","journal-title":"Cancers"},{"issue":"3","key":"8100_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","volume":"30","author":"C Contal","year":"1999","unstructured":"Contal C, O\u2019Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal. 1999;30(3):253\u201370.","journal-title":"Comput Stat Data Anal"},{"issue":"9596","key":"8100_CR13","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"},{"issue":"12","key":"8100_CR14","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00259-010-1570-6","volume":"37","author":"T Poisson","year":"2010","unstructured":"Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S, et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(12):2277\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"8100_CR15","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1089\/thy.2023.0164","volume":"33","author":"A Jannin","year":"2023","unstructured":"Jannin A, Giudici F, de la Fouchardi\u00e8re C, Al Ghuzlan A, Wassermann J, Chougnet CN, et al. Factors associated with survival in anaplastic thyroid carcinoma: A multicenter study from the ENDOCAN-TUTHYREF network. Thyroid. 2023;33(10):1190\u2013200.","journal-title":"Thyroid"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08100-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08100-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:31:50Z","timestamp":1790929910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08100-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8100"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08100-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. This study was deemed not subject to the Medical Research Involving Human Subjects Act (Wet medisch-wetenschappelijk onderzoek met mensen, WMO) by the Medical Ethics Review Committee of the Erasmus Medical Center under the protocol \u201cTreatment details of the Anaplastic thyroid cancer Patient in the Netherlands\u201d (MEC-2021-0324).","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study. For deceased patients, informed consent was not required as per the approval of the Erasmus Medical Center medical-ethical committee under the protocol (MEC-2021-0324).","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose pertaining to this manuscript. Schelto Kruijff is an editor in this journal.","order":3,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have declared a competing interest pertaining to this work.","order":4,"name":"Ethics","label":"Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}